Alliance Wealth Advisors LLC UT Acquires New Stake in DexCom, Inc. (NASDAQ:DXCM)

Alliance Wealth Advisors LLC UT bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 3,816 shares of the medical device company’s stock, valued at approximately $297,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC raised its position in DexCom by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock valued at $664,056,000 after buying an additional 214,136 shares during the last quarter. Jennison Associates LLC boosted its position in DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock worth $594,455,000 after acquiring an additional 710,858 shares during the last quarter. Groupama Asset Managment grew its stake in shares of DexCom by 1.1% during the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after acquiring an additional 31,358 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in shares of DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of DexCom by 11.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock worth $183,298,000 after purchasing an additional 288,381 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 4,259 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on DXCM. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Oppenheimer lowered their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Leerink Partners dropped their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. JPMorgan Chase & Co. raised their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Finally, StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $98.41.

DexCom Stock Up 0.5 %

Shares of DXCM opened at $87.46 on Wednesday. The firm has a market cap of $34.16 billion, a P/E ratio of 52.37, a price-to-earnings-growth ratio of 2.23 and a beta of 1.14. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The firm’s 50-day simple moving average is $80.95 and its 200 day simple moving average is $75.77.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.